Coaches charge to launch the stores, a Chinese wholesaler’s price sheet and a U.S. fulfillment company show how they are supplied, testing labs provide the certificates, and recruiting posts offer affiliates 10 to 40 percent. One seller who teaches others puts his net margin at 55 percent.
I rechecked 23 research-peptide stores that had an FDA warning letter or an August Lilly lawsuit. Eight still listed the cited products under the same names, one listed them under new names, six had taken down the cited pages, four kept their catalog behind a login and four were unreachable. The FDA has posted no close-out letter for any of the 19 warning letters.
On October 9, 2026, I checked 93 research-peptide storefronts for things FDA warning letters cite as evidence that a “research use only” product is meant for people. Twenty-three publish mixing or dosing instructions, a dosing calculator or claims about effects in people. Another 24 list bacteriostatic water. The label has been in federal plea cases since 2013.
In TRIUMPH-1, 22.5% of people on retatrutide’s 12 mg dose had it cut, most often for perceived excessive weight loss, and they still count toward the 28.3%. What that says about 4 mg.
The brenipatide Phase 3 program is Lilly’s bet that it can reach an alcohol and depression label before anyone else, and it pulls a possible approval years closer. Key Points Lilly sent brenipatide, an experimental GIP/GLP-1 drug, straight from Phase 1 into Phase 3 for alcohol use disorder and major depression, skipping the mid-stage trial
Updated September 26, 2026 with Lilly’s first Phase 1 safety data and a note that the drug is dosed weekly, not monthly. Brenipatide side effects: thirteen registered trials, ten conditions, and not one has reported. Here is what is actually known. I take tirzepatide every Friday, so I know exactly what a GLP-1 does to
I paid Lilly’s self-pay price for Zepbound for months, and retatrutide has no announced price yet, so here is what Lilly’s own price ladders imply.
CagriSema has no announced brand name as of September 4, 2026. Novo Nordisk owns eleven invented names it could use, and it bought the matching web address for only six of them.
CagriSema is not approved, so Medicare does not cover it. Here are the three routes after the FDA decides: the $50 Medicare GLP-1 Bridge, regular Part D, or the CagriSema cost without insurance.
Novo’s own head-to-head could not show CagriSema was as good as tirzepatide. I take Zepbound myself, and I go through both sets of numbers, plus the brand names Novo has filed, including Wegovamy.
